Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX prophylaxis, suffer severe hemorrhages, or recurrent serious bleeding.

In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses what other tactics healthcare marketers can utilize to connect with diverse audiences on a deeper level

The latest news for pharma industry insiders.

PanOmiQ is referred to as the fasted technology of its kind by the company.

Melton, customer advocacy executive at Magnolia, discusses how new technologies can be used to ensure data is accurate.

The center will offer local residents with opportunities and training to enter the pharmacy work force.

Companies reported that the new formulation of Coartem met required pharmacokinetic profiles and displayed promising efficacy and safety treating malaria in infants.

Pivya has shown efficacy against bacteria strains such as Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.

Sanders wrote a letter to Novo Nordisk announcing the investigation.

In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but address their specific healthcare needs

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides a look into the potential of further indications for Coya 302 amid promising ALS study.

AI allows patients, doctors, and payers to make informed decisions based on evidence at a much faster pace.

The latest news for pharma industry insiders.

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a preview on what the nexts steps are after presenting positive data on Coya 302 for the treatment of ALS.

Company aims to provide affordable emergency treatment from overdoses of heroin, fentanyl, and prescription opioids.

In this Pharmaceutical Executive video interview, Jon Hamrick, Partner, Curatio Scientia Advisors and Jon Rawlson, President & Founder, Armory Hill Advocates, speak about what kind of impact their survey's findings impact will be on the industry.

Ojemda is the first systemic therapy approved by the FDA for the treatment of relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or a BRAF V600 mutation.

Healthcare customers and patients are facing more avenues to receive misinformation about drugs than ever before.

The latest news for pharma industry insiders.

Lutathera is the first FDA-approved treatment for younger patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Approval comes amid positive results of a single-arm trial, showing a complete response rate of 77% in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

In this Pharmaceutical Executive video interview, Jon Hamrick, Partner, Curatio Scientia Advisors and Jon Rawlson, President & Founder, Armory Hill Advocates, discuss what’s stopping companies from investing in covering state level legislation and regulations impacting patient services, access, and affordability.

Leaders in areas such as drug discovery, clinical development and market access will meet to discuss AI, failing life expectancy, and a new generation of talent.

LabConnect will utilize the consulting firm’s assets to improve its clinical trial services.